Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BC 3195

Next Previous
Drug Profile

BC 3195

Alternative Names: BC-3195

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocity Biopharmaceutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
  • Mechanism of Action Apoprotein stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 May 2025 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 13 Mar 2025 BioCity Biopharmaceuticals and Merck Sharp & Dohme agree to a clinical collaboration for BC 3195 for Solid tumours
  • 13 Mar 2025 Biocity Biopharmaceutics plans a phase I/II trial for Solid tumours (Metastatic disease, Late-stage disease, Combination therapy) in fourth quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top